<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T01:29:06Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/11245" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/11245</identifier><datestamp>2026-09-24T18:37:20Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Wan, Yonghong</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Brian Lichty, Jonathan Bramson</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Brian Lichty, Jonathan Bramson</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Zhang, Liang</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences (Molecular Virology and Immunology Program)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T16:54:02Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T16:54:02Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2011-09-22</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2011-10</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/6227</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">7249</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">2251771</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/11245</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/19574</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>Cancer vaccine therapy aims at harnessing effective antigen specific immune responses to treat tumor. In particular, CD8+ T cells have the unique capacity to recognize and destroy tumor cell throughout the body. One potential approach to elicit high numbers of effector CD8+ T cells to control tumor growth is through repeated vaccination, a strategy called prime-boost vaccination. However, booster immunization is relatively inefficient during primary immune response because pre-activated effector T cells tend to impair robust antigen presentation. This phenomenon has been interpreted as a negative feedback mechanism where recently activated CD8+ T cells clear the antigen-bearing dendritic cells (DCs) and prevent memory T cells from the access of the boosting antigen. Interestingly, however, using in vitro activated B cell as a viral vector delivery system, we can boost T cell responses with the minimum viral input at a very short interval between immunizations. This B cell carrier is capable of delivering different viral vectors expressing different antigens, displaying a potential for broad application. The mechanisms behind B cell carrier-mediated efficient secondary responses are three fold: 1. Without the engagement of MHC molecules and antigen presentation, B cell carrying viral vector can bypass the killing by pre-existing effector T cells 2. B cells can delivery viruses to B cell follicles, a place separated from effector T cells, and mediate memory T cell expansion. 3. B cells can deliver antigen to both spleen and lymph node and induce antigen specific T cell expansion in multiple lymphoid organs. Our studies provide a novel boosting platform to accelerate CTL responses that has important clinical implications.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">cancer immunotherapy</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">cellular immunity</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">viral antigen delivery</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Immunology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Immunology</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">The utilization of activated B cell for cell carrier for viral vectored antigen delivery in the acceleration of CD8 T cell recall response</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>